NCT06712316 2026-03-17
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
BioNTech SE
Phase 2/3 Recruiting
Clinical Trials
19 trialsNCT07063745 2026-03-17
MountainTAP-29
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT07100080 2026-03-03
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT06236438 2026-02-23
LIVIGNO-4
AbbVie
Phase 2/3 Recruiting
NCT04619797 2026-02-03
SKYSCRAPER-06
Hoffmann-La Roche
Phase 2/3 Completed
NCT07131319 2026-02-02
SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC
Second Affiliated Hospital of Nanchang University
Phase 2/3 Recruiting
NCT07365319 2026-01-26
TeLuRide-008
Eikon Therapeutics
Phase 2/3 Not yet recruiting
NCT05800015 2026-01-22
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
Regeneron Pharmaceuticals
Phase 2/3 Active not recruiting
NCT05096663 2025-05-15
Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
SWOG Cancer Research Network
Phase 2/3 Active not recruiting
NCT02784171 2024-12-10
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
Canadian Cancer Trials Group
Phase 2/3 Completed
NCT06335355 2024-03-28
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients
Shanghai Shengdi Pharmaceutical Co., Ltd
Phase 2/3 Not yet recruiting
NCT03380468 2023-07-20
ECTOP-1004
Fudan University
Phase 2/3 Unknown
NCT05209256 2022-01-26
Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
The First Affiliated Hospital of Henan University of Science and Technology
Phase 2/3 Unknown
NCT04750083 2021-02-11
HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 2/3 Unknown
NCT01774578 2020-05-28
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Lumos Pharma
Phase 2/3 Terminated
NCT01907100 2019-03-18
Nintedanib (BIBF 1120) in Mesothelioma
Boehringer Ingelheim
Phase 2/3 Terminated
NCT01383148 2017-01-05
TIME
Transgene
Phase 2/3 Terminated
NCT01769066 2016-02-23
Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
Fudan University
Phase 2/3 Completed
NCT01481259 2012-07-03
Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer
People's Hospital of Guangxi Zhuang Autonomous Region
Phase 2/3 Unknown